Correlation analysis in the TCGA-PRAD dataset indicated that POLD1, SLC26A6, and TELO2 expression was significantly higher in pathological T3 and T4 stages than in T2 stage, and in pathological N1 stage compared to N0 stage (Fig. 9C-D). Here, SLC26A6 is linked to prostate adenocarcinoma.